Fangfang Duan

Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study

Xiaoli Zhao, Fangfang Duan, T. Kong, 2022, Investigational New Drugs.